Introduction
Around five million Americans suffer from chronic heart failure (CHF) 1 . The most common causes for the development of CHF are chronic arterial hypertension, myocardial hypertrophy and previous myocardial infarction 1 . The progression of heart failure is driven by pathological ventricular remodeling processes, which mainly involve cardiomyocyte hypertrophy, myocardial fibrosis and profound changes in gene-expression that together lead to left ventricular dilation and systolic as well as diastolic dysfunction over time [2] [3] [4] . Despite recent therapeutic advances, the mortality of CHF remains high, and -a fact that is somewhat neglected -strikingly different between women and men. Women with heart failure have a lower mortality compared to men and also a better prognosis when suffering from hypertension, aortic valve stenosis or hypertrophic cardiomyopathy 1, 5 . Sex hormones might account for these differences and indeed the expression of androgen as well as estrogen receptors was found in male and female hearts, implying that estrogen and androgens could directly act on the myocardium 6, 7 . While in general estrogen has been deemed cardioprotective, large randomized and controlled studies have failed to demonstrate beneficial effects of estrogen therapy in postmenopausal women 8, 9 . As a consequence, it is now proposed that the rise in cardiovascular mortality in women after the onset of menopause might be caused by an increased ovarian production of testosterone 10 .
Testosterone and its highly active metabolite dihydrotestosterone (DHT) operate by binding to the androgen receptor, which can act as a ligand dependent transcription factor, but also in a so called "non-genomic" fashion by potently influencing cellular signal-transduction 11 .
Recent data point towards a pro-hypertrophic effect of testosterone and DHT on isolated cardiomyocytes and in mice 7, 12, 13 . However, it remains unclear whether inhibition of androgens might be beneficial during heart failure or hypertrophy, and how anti-androgenic therapy should and also a better prognosis when suffering from hypertension, aortic valve stenos os si is o or m hypertrophic cardiomyopathy 1, 5 . Sex hormones might account for these differences and indeed h he e ex ex exp pr pres es ssi si sion on o of f f a an androgen as well as estrogen r rec ec e e ep ptors was fou und nd n in n ma m male and female hearts, m mp pl plyi y ng that es est tr t o og ogen en n a a and nd nd a a and nd ndro roge ge gen n ns co co ould d d di irec ct tly y y ac ct ct o on n th h he e m my myoc car ar rdi ium um m 6 6, 6, 7 7 7 . . Wh Wh Whil il ile e in in g g gen en ner er ral es str tr trog og ogen en e h has as as b b bee een n de dee em med ed e car ar ardi di diop op opro ro rote tect ct c iv iv ive, e, e, lar ar arg g ge e ra a and nd dom m miz iz ized d d a an nd nd c c con on o t t tro ol olle led d d st st stud ud die ie ies s h ha av ve ve f fa a aile e ed d o demonstra ate te e b b ben en nef ef e ic ic cia ia al ef ef effe fe fect t ts s s of of of es e e tr tr trog og ogen en n t t the he hera ra rapy py py i in n po po post st stme me meno no nopa pa aus us usal al al w w wom om o en en en 8 8 8, 9 9 9 . . As A A a be conducted, since complete blockade of androgen action is typically associated with severe side-effects 14 .In this study, we analyzed whether treatment with finasteride, a drug that is currently used for the therapy of benign prostate hyperplasia reduces cardiac hypertrophy and failure in mice 14 . Finasteride specifically inhibits isoforms 2 and 3 of the 5--reductase, the enzyme that converts testosterone to DHT, which is the most potent androgen of the body and about 10-fold more potent than testosterone [14] [15] [16] . We show here that finasteride by reducing DHT levels, very effectively reverses pathological hypertrophy, fibrosis and left ventricular dysfunction in mice of both sexes.
Methods
An expanded Methods section is provided in the Supplemental Material. Transverse aortic constriction (TAC) was performed in 8-to 10 week old C57/Bl6N mice (Charles River) around a 25-gauge needle as previously described 17 . Hemizygous transgenic mice expressing the entire coding region of the G q protein under the control of the -myosin heavy chain promoter have been described before and were obtained from the Jackson laboratory 18 . Littermate mice not carrying the transgene (wild-type, WT) were used as control. Echocardiography was performed with a linear 30MHz transducer (Visualsonics, Toronto, Canada) in mice that were sedated with 1-1.5% isoflurane. LV end-diastolic area (LVEDA) and end-systolic area (LVESA) were recorded. Fractional area change was calculated as [(LVEDA-LVESA)/LVEDA] x 100. Left ventricular pressures were assessed with a microtip pressure-volume catheter (PVR-1000, Millar
Instruments, Houston, TX) inserted through the cardiac apex during anesthesia with 2%
isoflurane. Finasteride (Sigma Aldrich, St. Louis, MO) was administered daily by oral gavage as suspension in 0.5% methyl cellulose at a dose of 25mg/kg/day. At the end of the experiments,
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Neonatal rat ventricular cardiomyocytes (NRCMs) were isolated from 1-3 day old Sprague-Dawley rats by Percoll density gradient centrifugation as previously described 19 . On the day after isolation, the cells were switched to serum free media and incubated with phenylephrine (20μM), fetal bovine serum (FBS, 2%), testosterone (1μM), dihydrotestosterone RNA from cultured cardiomyocytes, mouse hearts or human hearts was isolated with the Trifast reagent (Peqlab, Erlangen, Germany). The human heart samples used in this study were in part described previously and obtained after death, explantation or left ventricular assist device implantation with previous institutional review board approval of the Massachusetts General
Hospital and the Medizinische Hochschule Hannover 20 . cDNA synthesis and quantitative PCR was performed using standard procedures and the MX4000 multiplex QPCR system from Stratagene. The PCR primers are listed in the Supplemental Table. Western blotting was performed using standard procedures, as described 17 .
Transversal frozen sections of the myocardium were generated to measure cardiomyocyte cross-sectional area after staining the cardiomyocyte cell membrane with tetramethyl rhodamine Ad.dnAkt) were added to the cells for two hours on the day after isolation, and d s s sti timu mu m la la lati ti ion on on w wi ith FBS and finasteride was subsequently conducted. Cell size was determined by planimetry after m mmu mu mun no no f -f -flu lu luor ores sce ce cen nc nce staining for Troponin I (H H H--1 -7 7 70, Santa Cruz z B Bio ote te tec ch chnology).
isothiocyanate-conjugated wheat-germ agglutinin (WGA, Sigma Aldrich). Fibrosis was quantified with the Sirius Red staining method.
We used the AbsoluteIDQ Stero17 kit (Biocrates, Innsbruck, Austria) to assess the concentrations of testosterone, DHT, estradiol and androstendione in mouse serum. The procedure uses a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method and was conducted according to the manufacturer´s instructions as described 21 .
Statistical Analysis
All values are presented as means ± SEM. The Mann-Whitney test was used for comparisons between two groups. Differences between three or more groups were analyzed with the KruskalWallis test followed by Dunn´s multiple comparison´s test. Differences between three or more groups in cardiomyocyte cell size in vitro were analyzed by one-way analysis of variance followed by Sidak`s multiple comparisons test. Mouse mortality after TAC surgery was analyzed by the log-rank test. A two-tailed P value of less than 0.05 was considered significant. All statistics were calculated with the Graph Pad Prism 6 software.
Results

The expression of 5--reductase isoforms is induced in cardiac hypertrophy
Finasteride inhibits isoforms 2 and 3 of the 5-alpha-reductase enzyme that converts testosterone to the more active metabolite DHT. We assessed the expression of all three isoforms of this enzyme (Srd5a1-Srd5a3) in different pathological conditions associated with cardiomyocyte hypertrophy. Absolute quantification in human myocardial samples revealed Srd5a3 as the most abundantly expressed isoform of the heart (Figure1A). Srd5a3 mRNA was significantly induced in human hearts with hypertrophy, while it was unchanged in hearts from patients with endstage
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Finasteride reduces increased myocardial DHT in the hypertrophic myocardium
Because isoforms of the DHT producing enzyme 5--reductase were upregulated in cardiac hypertrophy, we measured the expression of Mt1, Odc1 and Axin1 mRNA as DHT responsive genes by real-time PCR in the myocardium of mice after TAC or sham surgery subjected to daily treatment with finasteride (starting one week after surgery for two weeks) 22 . Male mice exerted mildly induced expression of Mt1, Odc1 and Axin1 after TAC (Figure 2A) . In response to finasteride, Mt1 and Odc1 mRNA were strongly downregulated -even below the level observed in sham operated mice -after TAC, while Axin1 expression was not influenced. We also found a robust myocardial induction of Mt1, Odc1 and Axin1 after TAC in female mice, which was attenuated by finasteride treatment ( Figure 2B ). To measure myocardial DHT abundance more directly in myocardial samples, we used an antibody raised against protein-bound DHT. In
Western blots of isolated NRCMs probed with this antibody, we identified a specific protein band at 25kDa that was markedly diminished in cardiomyocytes incubated with finasteride, indicating that this band represented a DHT-protein complex ( Figure 2C ). We found an induction of this DHT-protein complex after TAC in untreated male and female, but not in finasteride treated mice ( Figure 2D ). Interestingly, we also observed increased DHT-protein in Figure 2E ). In summary, we found strong evidence for increased myocardial DHT levels in hypertrophic hearts that were effectively reduced by finasteride.
Finasteride inhibits cardiomyocyte hypertrophy in vitro
We first investigated the functional impact of finasteride on hypertrophy in NRCMs. As depicted in Figure 3A and B, phenylephrine and FBS led to significant cardiomyocyte hypertrophy with increased cell size and induction of BNP mRNA expression. The increase in cell size in response to both stimuli was significantly blunted by finasteride as was the increase in BNP in response to FBS, but not in response to phenylephrine. Because we hypothesized that finasteride reduced cardiomyocyte hypertrophy through a reduction of DHT abundance, we tested whether DHT induced cardiomyocyte hypertrophy and whether finasteride still inhibited hypertrophy when DHT was present in excess. As shown in Figure 3C and D, testosterone and DHT both induced cardiac myocyte hypertrophy, while only the testosterone induced cell growth, but not that by DHT could be inhibited by finasteride. Incubation of NRCM with the androgen receptor inhibitor flutamide blocked phenylephrine induced hypertrophy to a similar extent as finasteride ( Figure   3E ), which also did not exert an additional anti-hypertrophic effect in the presence of flutamide, suggesting that both agents act through a similar cellular target, i.e. androgen induced signaling.
Thus, finasteride efficiently inhibits cardiomyocyte hypertrophy induced by different stimuli, depending on its capability to reduce DHT levels and androgen receptor activation.
Finasteride therapy inhibits cardiac hypertrophy and dysfunction in male and female mice
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Echocardiographic examination revealed an improved left ventricular systolic function
(measured as fractional area change, Figure 4B ) and a significantly reduced cardiac dilation (enddiastolic area after TAC; 13.7±0.7 versus 11±0.6 mm 2 ) in response to finasteride treatment.
Fibrosis was reduced in TAC mice after finasteride administration, which was supported by a reduced collagen3 mRNA expression ( Figure 4C and E, F). Finasteride had no effect in sham operated mice ( Al Alth th hou o ough gh h f f fem ema a ale e e mi m ce ce e i i in n n ge ge gen ne ner ra ral l l ha ha have ve v f f far ar lo ow owe er e sy sy sys st stem em emic ic c l lev ev evel el ls s o of of t te es esto to tost ster er ero o one e e an an nd d DH DH DHT T both hormon nes es es w w wer er ere e un un unde e er r r th th the le le leve ve vel l l of of f d d det et e ec ec ecti ti t on on on o o of f o our ur r a a ass ss ssay ay ay i i in n n se e eru ru rum, m, m, d d dat at ata a no no not t t sh sh show ow own), we stil ll f f f levels, in order to rule out that finasteride treatment led to an increased abundance of estradiol, but no difference was found among groups (Supplemental Figure 3B ).
Finasteride improves cardiac function and reduces mortality in heart failure
To assess whether finasteride treatment is also beneficial in advanced myocardial disease, we started it 21 days after TAC or sham surgery in male mice and continued for 32 days ( Figure   6A ). We found a significantly reduced mortality after TAC in the finasteride treated mice ( Figure 6B ). After four weeks of finasteride treatment, mice had a better systolic function compared to untreated mice ( Figure 6C ). Millar-catheterization revealed an improved cardiac relaxation (dp/dt min and Tau) and a trend towards better contractility (dp/dt max) after TAC ( Figure 6D ). There was no difference in these parameters in sham treated mice. Intraventricular systolic blood pressure rose to a similar extent after TAC in treated and untreated mice, indicating that both groups of mice were exposed to a similar amount of pressure overload (Supplemental Figure 2C ). In addition, systolic blood pressure was similar in untreated and treated sham operated mice, thus excluding a direct effect of finasteride on systolic blood pressure (Supplemental Figure 2C ). Because androgens (especially testosterone) positively regulate skeletal muscle mass, we analyzed skeletal muscle weights in the different treatment groups, but no differences were observed (Supplemental Figure 4A) .
Finasteride improves cardiac function in G q triggered cardiomyopathy
Next, we wanted to test whether finasteride also ameliorates cardiac dysfunction in another model of heart failure. G q transgenic mice were described as model for cardiac failure with pronounced ventricular dilation. We started to treat male G q transgenic (TG) mice with finasteride at the age of eight weeks and continued the daily treatment for six weeks ( Figure   7A ). Untreated TG mice as well as treated and untreated WT mice were used as controls. As Figure 6D ). There was no difference in these parameters in sham treated mice. I I Int ntra r r ve ve vent nt ntri ri ricu cu c la lar ystolic blood pressure rose to a similar extent after TAC in treated and untreated mice, n ndi di ica ca cati ti ting ng g t t tha ha hat bo bo oth th th groups of mice were expose e ed d 
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Fi Fina na nall ll lly, y, y, w we e e in in inve ves s stig ig gat ated ed h how ow w t the he he re re red du duc ct ctio io ons ns ns of f f DH DH DHT T T le e eve ve els ls ls b by y y fi fin na nast st ster er e i i ide e e le lead ad a t t to o it it its s s pr pron on onou oun n nce ed ed anti-hypertrop op ophi hi hic c ef ef effe fe f ct ct cts. s T T Tes es sto tost st ster er e on on o e e is is i k k kno no now w wn n to to to a a act c iv iv vat at ate e e si si s gn gn gnal a a in in ng g g mo mo mole le lecu cu c le le les s s in in in c c car ar a diac finasteride at this time point, the phosphorylation of p70S6K as mTOR target was induced by FBS treatment, but not in the cells that were pretreated with finasteride. However, this effect was rescued, at least partially, when DHT was added in abundance to the culture medium, indicating that the reduction of DHT was required for finasteride triggered mTOR inhibition. In order to investigate whether modulation of signaling is responsible for the anti-hypertrophic effects of finasteride, we transduced NRCMs with an adenovirus encoding for an activated form of Akt 
Discussion
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DHT, the most potent endogenous androgen, has a two-to five-fold higher binding capacity to the androgen receptor and a 10-fold higher potency to induce androgen receptor mediated signaling than testosterone 14 . As a consequence, the main physiological function of DHT seems to be the amplification of testosterone mediated signals, for example during the development of male and female reproductive organs 23 . Testosterone is converted to DHT by isoforms 1 -3 (Srd5a1-Srd5a3) of the 5--reductase, while Srd5a3 is also involved in N-linked protein glycosylation 14, 24, 25 . Each of the three enzymes is expressed at similar levels in the heart of male and female mice, and finasteride operates mainly as an inhibitor of Srd5a2 and Srd5a3 26 .
We demonstrated here that Srd5a3 is the predominant cardiac isoform and that the expression of all 5--reductase isoforms is increased in human and mouse hypertrophic heart disease. We reasoned that, not unlike in the prostate where Srd5a1-3 are highly expressed and as a result DHT is the most prevalent androgen 14 , increased Srd5a isoform expression in response to hypertrophic stimulation in the heart leads to increased abundance of DHT, which can be reduced by finasteride. Indeed, measurement of DHT responsive genes as well as DHT-protein complex verified this hypothesis. Although our methods to determine DHT levels in the myocardium are indirect, the detection of reduced DHT in response to finasteride argues in favor of their specificity. In support of our findings, increased levels of DHT production were previously found in ex vivo preparation of microsomes from human hypertrophic hearts 27 .
In order to mimic a clinical situation, in which no prophylactic therapy is feasible, finasteride treatment was started when disease (i.e. hypertrophy/left ventricular dysfunction) was already present in our mice. Despite this late treatment start, finasteride reduced mortality, of male and female mice, and finasteride operates mainly as an inhibitor of Srd5 5a a2 a2 a a and nd d S S Srd rd rd5a 5a 5a3 3 26 .
We demonstrated here that Srd5a3 is the predominant cardiac isoform and that the expression of f f al ll l 5-5-5--r -red ed educ uc u t t tase e e i i is so soforms is increased in human n n a an n nd mouse hyper er rtr t op phi hi hic c c heart disease. We e eas s son o ed that, n no o ot u unl nl lik i i e e e in in in t t the he he p pro ro os st stat ate e w whe e ere e e Srd5 d5 d5a1--3 -3 a are re e h h hig igh h hly y y ex exp p pre e esse se ed d d an and d d as as s a a r res es sul ult t t DH DH HT T T is is is t the he e m m mos ost t t pr pr rev eva ale en ent t an n ndr dr rog og ogen en en 14 , , in in ncr cr crea ea e se se sed d Sr r rd5 d5 5a a is is iso of ofor or rm m m ex ex xpr pr pres es ssi i ion on i i in n re re r sp sp spo o onse se e t to o hypertrophic c s s sti ti timu mu mula la lati ti ion on on in n n th th the he he hear ar rt t t le e ead ad ads s s to to to i i inc nc n re re reas as ased ed a a abu bu protective effects on the myocardium in the setting of ischemia/reperfusion injury 33 . Systemic deletion of the androgen receptor protected male mice from pathological hypertrophy, althoughin contradiction to the gonadectomy based studies -it also triggered cardiac dysfunction and fibrosis 13 . The reason for this discrepancy remains unclear, but could be the consequence of complex secondary effects due to the testicular feminization syndrome observed in these global androgen receptor knock-out mice 11 . Interestingly, and also striking to us was the fact that finasteride was similar effective to improve ventricular remodeling after TAC in pre-menopausal female compared to male mice. The impact of male sex hormones on the female myocardium is far less well studied. However, in accordance with the fact that androgen receptor expression in the myocardium of females was similarly high compared to males in humans and mice, administration of testosterone or DHT was sufficient to induce adverse ventricular remodeling and hypertrophy in female mice and rats as well as in isolated cardiomyocytes 7, 12, 34 . Although the total levels of cardiac DHT are very likely to be higher in male than in pre-menopausal protective effects on the myocardium in the setting of ischemia/reperfusion injur ry y y 33 33 33 . Sy Sy Syst st stem em emic i ic deletion of the androgen receptor protected male mice from pathological hypertrophy, althoughn n c c con on ontr tr trad ad adic ic icti ti tio on t t to o o th the gonadectomy based studie ie es s --it also triggere re ed ca ca ard rd rdia i c dysfunction and fi fi ibr r ros o is 13 . The e re re eas s son on f for or or t t th hi his s s d di disc sc cre re repa panc nc cy re e em m main ns s u unc cl cle ea ear, r, b but ut c c cou u uld ld b b be th the e e c co cons nse eq eque ue u n n nce e e of of of co omp mp mple le lex x se se eco co cond nda a ary y y ef ef ffe fect ct c s s du du due to to to t t the he h t t tes es sti ti ticu cu cula a ar r r f fem em emin i i iz izat at atio io ion n sy sy syn nd ndro ro rome me me o obs bser er erve ve ed d in in in t the e ese e e g glo lo oba ba al l r r r androgen rec cep ep epto to t r r r kn kn knoc oc o k-k k ou ou out t t mi mi ice ce ce 11 11 11 . . In n nte te tere re rest st s in in ingl gl gly, y, y, a a and n n a a als ls lso o o st st stri ri riki ki k ng ng g t t to o o us us us w w was as t the he he f f fac ac act t that Despite ample evidence of detrimental androgen effects on the myocardium, data from epidemiologic studies and clinical trials have suggested beneficial systemic effects of testosterone replacement therapy in testosterone deficient men with heart failure. This low dose testosterone replacement therapy particularly improves the exercise capacity, but not left ventricular function, most likely by increasing skeletal muscle mass [35] [36] [37] . In our study, chronic finasteride treatment had no negative effect on skeletal muscle mass. This is in line with a previous study in hypogonadal men, in which low dose testosterone and finasteride treatment were combined, resulting in increased skeletal muscle mass from testosterone, but prevention of deleterious DHT effects on the prostate as a consequence of finasteride administration 38 .
How did finasteride inhibit cardiac hypertrophy? We demonstrated here that finasteride inhibits activation of important pro-hypertrophic signaling molecules like Akt and its downstream target mTOR in hypertrophied isolated cardiomyocytes in vitro as well as in the mouse myocardium after TAC in vivo. The action of finasteride on hypertrophy and signaling were dependent on its capability to reduce DHT levels, since addition of DHT in abundance prevented its growth inhibiting properties and ameliorated its impact on mTOR dependent signaling. Finasteride could not inhibit the activation of a constitutive active form of Akt and was no longer effective in reducing hypertrophy in cardiomyocytes expressing activated Akt. In addition, Akt was necessary for the anti-hypertrophic action of finasteride, since inhibition of Akt with a dominant negative construct ablated its effects. Thus, we concluded that modulation of signaling by finasteride was required for its anti-hypertrophic effects and that its impact on cellular signal transduction occurred upstream of Akt. A diminished expression of RCAN1.4
were combined, resulting in increased skeletal muscle mass from testosterone, b bu u ut p p pre reve v vent nt ntio io ion n o of deleterious DHT effects on the prostate as a consequence of finasteride administration 38 .
Ho Ho How w w d d did d fi fi fin na nasteride inhibit cardiac hype ert rt rtro rophy?
We demo mo onstr trat at ate e ed here that finasteride n nhi i ib bits activat atio io ion of f f i i imp mp por or orta ta ant nt nt p pro ro ro--h -hy yp pe e ertro op oph hic si sig gna al ali in ng g mo m mole lecu cu ule les li l l k ke e A A Akt kt kt a and nd nd i i its ts t do down wn wnst st stre ream am m t t tar arg g get t t mT mT TO OR OR in n hy hy hype pe pert rt rtro roph ph phie ie ied d d isol ol olat at ted ed d ca ar a di di dio om omyo yo yocy cy yte te es s s in in n v vit itro ro o a as s s we we well ll ll as s s in n n t the he e mouse myoc car ar ardi di d um um um a aft ft f er e e T T TAC AC AC in in in v viv iv ivo o. . Th Th The e ac ac acti ti ion on n o o of f f fi f na na nast st ster er erid id de e e on on on h h hyp yp yper er ertr tr trop op o hy hy hy a a and nd nd s signaling indicated reduced activation of the calcineurin/NFAT pathway in finasteride treated mice after TAC. This certainly contributed to the anti-hypertrophic effects of finasteride, although it could be the consequence of Akt inhibition, which not only results in reduced mTOR activity, but also leads to increased activation of FOXO transcription factors that were shown to inhibit calcineurin 39 . Testosterone dependent activation of cytosolic signaling molecules like Akt, ERK and mTOR and its contribution to androgen induced hypertrophy has been suggested previously 40, 41 . The impact of androgens on cellular signaling pathways is thought to occur within their "non-genomic" mode of action: instead of operating as a ligand induced transcription factor to regulate gene-expression in the nucleus, androgen receptor binding and activation by DHT occurs at the plasma-membrane, where the assembly of signaling complexes involving the phosphoinositide 3-kinase upstream of Akt is induced in response 42 .
In conclusion, finasteride effectively inhibits pathological hypertrophy and cardiac dysfunction in mice in response to pressure overload at different stages of the disease or in response to G q over-activation. Finasteride therapy is used as long-term treatment for prostate disease and is generally well tolerated, although rare side effects like sexual dysfunction, depression and high Gleason grade prostate cancer were described 43 . Another 5--reductase inhibitor, the more potent substance dutasteride (but not finasteride), has been associated with increased risk of heart failure development in one study of patients with prostate disease, although re-analysis of the data by the FDA corrected this effect to be statistically insignificant 44 .
In addition, a recent meta-analysis including more than 18000 patients could not verify any cardiovascular adverse events during dutasteride therapy 44 . Because finasteride was so effective to reduce cardiac hypertrophy and failure in mice and because of its clinical availability, we suggest that it should be evaluated as a treatment option in heart failure.
activation by DHT occurs at the plasma-membrane, where the assembly of signa ali l ling ng ng c c com om ompl pl plex ex e es e nvolving the phosphoinositide 3-kinase upstream of Akt is induced in response 42 .
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Limitation of this study
Although our data -especially the fact that we can reverse the anti-hypertrophic effects of finasteride by DHT in cardiomyocytes -speak against this, we cannot exclude that finasteride may protect the myocardium in vivo independent of its influence on the 5-alpha-reductase and DHT generation. In addition, whether our findings are as relevant in humans as in mice clearly needs further study, also because only a limited number of human myocardial tissue samples were examined here. Odc1 and Axi xi in1 n1 n1 m m mRN RN RNA A A le e eve ve vels l l w w wer er e e e e de e ete te t rm rm rmin in ined ed d b b by y y qu qu q an an anti ti tita ta tati ti t ve ve ve r r rea a al-l-l ti ti time me me P P PCR CR R a a as s s DH DH DHT Fractional area change determined by echocardiography (n=11-26/group). D, dp/dt max, dp/dt min and Tau were measured by Millar catheter in the left ventricle of the indicated mice (n=9-12/group). *p<0.05, **p<0.01, *** p<0.001, **** p<0.0001. *p<0.05, **p<0.01,*** p<0.001.
finasteride treated mice after TAC (n=14 untreated and n=15 finasteride treated a a anim im mal al als) s) s). . C, C, C, Fractional area change determined by echocardiography (n=11-26/group). D, dp/dt max, dp/dt mi min n n an an nd d d Ta Ta Tau u we were re re m measured by Millar catheter i i in n n th h he left ventricle le e of f th th the e e indicated mice (n=9-1 12 2/g g gro r up). *p< <0. 0. 0 05 5, ** ** * p< p< p<0 0. 0.01 01 01, ** ** ** p< p< p<0.001 1, * * **** * p p<0 0. 0.0 00 000 0 01. . To measure intraventricular pressures, animals were placed on temperaturecontrolled heating pad and core temperature was maintained at 37°C. A microtip pressure-volume catheter (PVR-1000; Millar Instruments, Houston, TX) was carefully inserted into the left ventricle, cardiac parameters were recorded using Labchart (ADInstrument Ltd. Oxford, UK) to calculate endsystolic and enddiastolic pressure and heart rate, as described Finasteride (Sigma Aldrich, St. Louis, MO) was administered daily by oral gavage as suspension in 0.5% methyl cellulose at a dose of 25mg/kg/day. In order to rule out the unlikely possibility, that the feeding procedure itself exerts beneficial effects after TAC and therefore accounts for the protective effects of finasteride, we analyzed another mouse cohort with the only difference that the mice, which did not receive finasteride were daily fed with NaCl (via an oralgastric tubing). As demonstrated in Supplemental Figure 1 , we also found reduced cardiac hypertrophy in the finasteride versus the NaCl treated group. Consequently, in the following experiments we used untreated mice as control for finasteride treatment. At the end of the experiments, mice were weighed and then euthanized. Hearts and lungs were quickly removed from the thoracic cavity. After removal of blood, the heart and lung weights were determined. All animal procedures were approved by our local state authorities.
Cell culture
Neonatal rat ventricular cardiomyocytes (NRCMs) were isolated from 1-3 day old Sprague-Dawley rats by Percoll density gradient centrifugation as previously described 4 . On the day after isolation, the cells were switched to serum free media and incubated with phenylephrine (20µM), fetal bovine serum (FBS, 2%), testosterone (1µM), dihydrotestosterone (DHT, 1µM) or vehicle with or without the addition of finasteride (25µM) and/or flutamide (10µM) as indicated. If needed, adenoviral vectors encoding for either β-galactosidase (Ad.Control), constitutive active proteinkinase B/Akt (Ad.caAkt) or dominant negative Akt (Ad.dnAkt) were added to the cells for two hours on the day after isolation, and stimulation with FBS and finasteride was subsequently conducted. Cell size was determined by planimetry after immuno-fluorescence staining for Troponin I (H-170, Santa Cruz Biotechnology). It was determined at least in duplicate cell culture dishes in at least two different cardiomyocyte isolations. Per culture dish, the size of a minimum of 100 cardiomyocytes was analyzed.
RNA isolation and real-time PCR
RNA from cultured cardiomyocytes, mouse hearts or human hearts was isolated with the Trifast reagent (Peqlab, Erlangen, Germany). The human heart samples used in this study were in part described previously and obtained after death, explantation or left ventricular assist device implantation with previous institutional review board approval of the Massachusetts General Hospital as well as of the Medizinische Hochschule Hannover 5 . Control human heart tissue was derived from victims of motor vehicle accidents, gunshot wounds or from healthy heart organ donors, when the organ was ineligible for transplantation. Hypertrophic human hearts were reported to be taken from patients initially considered as organ donors with known arterial hypertension without any history of congestive heart failure, but with marked cardiac hypertrophy as revealed by echocardiography and/or post-explant examination 5 . Failing human heart samples were derived from patients with end-stage heart failure undergoing cardiac transplantation or left ventricular assist device implantation. cDNA was generated from 
Serum levels of steroid hormones
We used the AbsoluteIDQ Stero17 kit (Biocrates, Innsbruck, Austria) to assess the concentrations of testosterone, DHT, estradiol and androstendione in mouse serum. The procedure uses a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method and was conducted according to the manufacturer´s instructions as described 6 .
Histological Analysis
Transversal frozen sections (7µm in thickness) of the myocardium were generated to measure cardiomyocyte cross-sectional area after staining the cardiomyocyte cell membrane with tetramethyl rhodamine isothiocyanate-conjugated wheat-germ agglutinin CIRCULATIONAHA/2014/012066/R1 (WGA, Sigma Aldrich). Fibrosis was quantified with the Sirius Red staining method.
Subsequently, the fraction of the fibrotic area (stained in red) from the total myocardial area was determined using Adobe Photoshop Imaging software.
Statistical Analysis
All values are presented as means ± SEM. The Mann-Whitney test was used for comparisons between two groups. Differences between three or more groups were analyzed with the Kruskal-Wallis test followed by Dunn´s multiple comparison´s test.
Differences between three or more groups in cardiomyocyte cell size in vitro were analyzed by one-way analysis of variance followed by Sidak`s multiple comparisons test 
